Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000370

Drug Information
NameAlfuzosin    
SynonymsSL 77499; LS-70106; MLS000759449; NCGC00095152-01; SL 77-499; 2-Furancarboxamide, N-(3-((4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-; AC1L1CWF; SAM001246638; Alfuzosine; KBioGR_001616; MolPort-003-666-623; Alfuzosina; Bio-0003; BSPBio_000323; Alfuzosina [Spanish]; UNII-90347YTW5F; Alfuzosine [French]; Prestwick3_000322; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide; BPBio1_000357; Alfuzosin (INN); CHEMBL709; 128707-53-9; CHEBI:51141; STK643675; Alfuzosinum [Latin]; Prestwick0_000322; NCGC00095152-05; SPBio_002244; BSPBio_002646; Alfusosine; Prestwick1_000322; DB00346; 86163-78-2; 81403-68-1 (hydrochloride); CPD000466340; NCGC00095152-03; Prestwick2_000322; KBio3_001866; MLS001424027; HMS2051I10; 81403-80-7; HMS1922P11; D07124; alphuzosine; CID2092; Alfuzosin [INN:BAN]; NCGC00095152-02; SMR000466340; L001317; SPECTRUM1505263; alfuzosin; Spectrum5_000817; HMS2093O06; BRD-A09056319-003-03-6; NCGC00095152-04; HSDB 7290; BRD-A09056319-001-02-2; AB00514667; Spectrum3_001063; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; Spectrum2_000505; C19H27N5O4; SPBio_000429; N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; Alfuzosinum; Spectrum4_001208; Xatral (TN)    
Trade NameUroxatral; Xatral    
CompanySanofi-Aventis    
IndicationBenign prostatic hyperplasiaApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAntihypertensive Agents    
CAS NumberCAS 81403-80-7
FormularC19H27N5O4    
PubChem Compound IDCID 2092.    
PubChem Substance IDSID 682525.    
ChEBI51141;    
SuperDrug ATC IDG04CA01;    
SuperDrug CAS ID081403807;    
TargetAlpha-1D adrenergic receptorAntagonist[2]
Ref 1Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. To Reference
Ref 2Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543